Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Closes Merck KGaA Merger, Looks To Fill Remaining Pipeline Gaps

Executive Summary

Following the close of its acquisition of Merck KGaA's generics unit, Mylan is looking to round out its product portfolio with oncology and women's healthcare products
Advertisement

Related Content

Chief Executive Change At Teva Illustrates Diversification Emphasis At Major Generic Drug Makers
Teva/Barr Merger Could Spell Opportunity For Smaller Generic Firms
Teva/Barr Merger Could Spell Opportunity For Smaller Generic Firms
Generic Firms Sanguine About New Congress, Preparing For Biogeneric Action
Generic Firms Sanguine About New Congress, Preparing For Biogeneric Action
Advertisement
UsernamePublicRestriction

Register

PS048867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel